Degenerative, non-atherosclerotic cardiovascular disease in the elderly: A clinico-pathological survey

1990 ◽  
Vol 2 (3) ◽  
pp. 231-244 ◽  
Author(s):  
Gaetano Thiene ◽  
M. Valente
Keyword(s):  
Cardiovascular Disease ◽  
The Elderly ◽  
Atherosclerotic Cardiovascular Disease

Abstract 17309: Scope and Determinants of Nonfinancial Barriers to Healthcare Access in Individuals With Atherosclerotic Cardiovascular Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Isaac Acquah ◽  
Javier Valero-Elizondo ◽  
Miguel Cainzos Achirica ◽  
Rahul Singh ◽  
Karan Shah ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Logistic Regression ◽  
Low Income ◽  
Barriers To Care ◽  
Multinomial Logistic Regression ◽  
The Elderly ◽  
Atherosclerotic Cardiovascular Disease ◽  
The Us ◽  
Barriers To Healthcare ◽  
Relative Prevalence

Introduction: Barriers to healthcare - financial and nonfinancial - may result in unmet health needs and adverse outcomes. Despite this, the nonfinancial barriers to care among adults with atherosclerotic cardiovascular disease (ASCVD) is poorly defined in the US. We aimed to explore the scope and determinants of nonfinancial barriers to care among individuals with ASCVD. Methods: We analyzed data from the 2013-17 National Health Interview Survey (NHIS). We included adults with self-reported ASCVD (heart attack, angina, and/or stroke). Nine key variables in the NHIS that represent nonfinancial barriers to healthcare were assessed as absent/present, and participants were classified as having 0-1, 2, or ≥3 barriers. Multinomial logistic regression (using 0-1 nonfinancial barriers as reference) was used to evaluate the relationship between various sociodemographic factors, and an increasing number of nonfinancial barriers. Results: Of all the 15,758 adults with ASCVD (8.1% annually in the US; representing 19.6 million), 23.4% reported having at least one nonfinancial barrier to care while 4.9% reported 3 nonfinancial barriers. In a multivariable multinomial logistic regression, after stratifying by age, individuals from low-income families had an almost 2-fold relative prevalence of 3 nonfinancial barriers ( Figure) . In the elderly, however, lack of insurance was the strongest predictor (relative prevalence ratio of 6.51 [95% confidence interval; 2.25, 18.87]) of having ≥3 barriers. Conclusion: Among adults with ASCVD, the relative prevalence of ≥3 nonfinancial barriers was low (4.9%) with low-income being the only modifiable predictor of reporting ≥3 nonfinancial barriers and lack of insurance being the strongest predictor in the elderly. Addressing financial barriers to healthcare may help alleviate these nonfinancial barriers.

scholarly journals Hypothesis

2016 ◽  
Vol 22 (1) ◽  
pp. 56-64 ◽  
Author(s):  
Wenguang Wang ◽  
Chao Liu ◽  
Hongliang Cong
Keyword(s):  
Cardiovascular Disease ◽  
Monoclonal Antibodies ◽  
Experimental Studies ◽  
The Elderly ◽  
Atherosclerotic Cardiovascular Disease ◽  
Calcific Aortic Valve Disease ◽  
Major Morbidity ◽  
Therapeutic Category ◽  
Potential Benefits ◽  
Calcification Inhibitors

Calcific aortic valve disease (CAVD) is a common cardiovascular disease in the elderly individuals associated with major morbidity and mortality. The process is characterized by multiple steps: lipid infiltration, inflammation, fibrosis, and calcification. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. Monoclonal antibodies of PCSK9 can result in substantial reductions in atherogenic lipoprotein cholesterol-carrying particles, especially lipoprotein(a), and thereby hold the potential for further reducing events associated with atherosclerotic cardiovascular disease. In this article, we reviewed the clinical and experimental studies in order to find the evidence of the involvement of PCSK9 in CAVD and the potential benefits of PCSK9 monoclonal antibodies in clinical therapeutics.

Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications

2018 ◽  
Vol 25 (13) ◽  
pp. 1480-1500 ◽  
Author(s):  
Sho-ichi Yamagishi ◽  
Takanori Matsui
Keyword(s):  
Cardiovascular Disease ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Visceral Obesity ◽  
Retinal Pigment Epithelial Cells ◽  
Atherosclerotic Cardiovascular Disease ◽  
Cardiometabolic Diseases ◽  
The Metabolic Syndrome ◽  
Pigment Epithelium Derived Factor ◽  
Cardiometabolic Disorders

Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.

Relationship of C-Reactive Protein to Risk of Cardiovascular Disease in the Elderly

1997 ◽  
Vol 17 (6) ◽  
pp. 1121-1127 ◽  
Author(s):  
Russell P. Tracy ◽  
Rozenn N. Lemaitre ◽  
Bruce M. Psaty ◽  
Diane G. Ives ◽  
Rhobert W. Evans ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
The Elderly ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Relationship Of

Plant n-3 PUFA intake may lower the risk of atherosclerotic cardiovascular disease only among subjects with a low intake of marine n-3 PUFAs

2021 ◽  
Author(s):  
Christian S. Bork ◽  
Søren Lundbye-Christensen ◽  
Stine K. Venø ◽  
Anne N. Lasota ◽  
Erik B. Schmidt ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pufa Intake

Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection

2021 ◽  
Vol 23 (5) ◽  
Author(s):  
Alison L. Bailey ◽  
Saif Al-Adwan ◽  
Eliea Sneij ◽  
Nicholas Campbell ◽  
Matthew E. Wiisanen
Keyword(s):  
Cardiovascular Disease ◽  
Hepatitis C ◽  
Viral Infection ◽  
Atherosclerotic Cardiovascular Disease

scholarly journals FACILITY LEVEL VARIATION IN THE REPORTING OF STATIN-ASSOCIATED SIDE EFFECTS AMONG PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

2021 ◽  
Vol 77 (18) ◽  
pp. 1509
Author(s):  
Xiaoming Jia ◽  
Michelle Lee ◽  
David Ramsey ◽  
Mahmoud Al Rifai ◽  
Dhruv Mahtta ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Atherosclerotic Cardiovascular Disease ◽  
Level Variation ◽  
Facility Level
Sign in / Sign up

Export Citation Format

Share Document